Residency · Baltimore, MD
Sponsored by University of Maryland Program
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Nature medicine · 2025 · 143 citations · Stefanie Mason
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics.
Nature cancer · 2024 · 117 citations · Shania Bailey
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.
Muscle & nerve · 2024 · 69 citations · Stefanie Mason
Significant Spirometric Transitions and Preserved Ratio Impaired Spirometry Among Ever Smokers.
Chest · 2022 · 98 citations · Stefanie Mason
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR).
Annals of neurology · 2023 · 86 citations · Stefanie Mason
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.
Scientific reports · 2025 · 27 citations · Stefanie Mason
Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.
Pediatric neurology · 2024 · 38 citations · Stefanie Mason
JAK inhibitors for asthma.
The Journal of allergy and clinical immunology · 2021 · 86 citations · Margaret Connolly